$SKYE
Skye Bioscience, Inc.

2021 Q4 Form 10-Q Financial Statement

#000151655121000020 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.348M $1.491M $948.9K
YoY Change 42.09% 25.12% -15.85%
% of Gross Profit
Research & Development $1.113M $327.7K $370.0K
YoY Change 200.91% -5.34% -48.32%
% of Gross Profit
Depreciation & Amortization $24.72K $7.460K $770.00
YoY Change 3110.39% 1916.22% 113.89%
% of Gross Profit
Operating Expenses $2.462M $1.819M $1.319M
YoY Change 86.64% 18.26% -28.46%
Operating Profit -$1.819M
YoY Change 18.26%
Interest Expense -$50.65K $195.4K -$183.2K
YoY Change -72.35% 6.98% -102.47%
% of Operating Profit
Other Income/Expense, Net -$5.709K
YoY Change -102.36%
Pretax Income -$2.512M -$1.825M -$1.502M
YoY Change 67.25% 40.73% -130.96%
Income Tax $500.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.513M -$1.825M -$1.502M
YoY Change 67.29% 40.73% -130.96%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$5.058K $0.00 -$5.001K
COMMON SHARES
Basic Shares Outstanding 476.1M shares 413.5M shares
Diluted Shares Outstanding 414.5M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.983M $11.09M $2.469M
YoY Change 263.77% 162.5% 34.94%
Cash & Equivalents $8.983M $11.09M $2.469M
Short-Term Investments
Other Short-Term Assets $56.87K $344.2K $275.00
YoY Change 20580.0% 10226.73% -96.36%
Inventory
Prepaid Expenses $554.2K $190.1K
Receivables
Other Receivables
Total Short-Term Assets $9.612M $11.43M $2.664M
YoY Change 260.76% 162.93% 33.57%
LONG-TERM ASSETS
Property, Plant & Equipment $87.71K $80.30K $7.341K
YoY Change 1094.8% 8952.65% 270.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.309K $8.309K $0.00
YoY Change
Total Long-Term Assets $243.0K $253.3K $7.341K
YoY Change 3210.05% 28454.57% 270.2%
TOTAL ASSETS
Total Short-Term Assets $9.612M $11.43M $2.664M
Total Long-Term Assets $243.0K $253.3K $7.341K
Total Assets $9.855M $11.69M $2.672M
YoY Change 268.87% 168.69% 33.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $897.9K $319.0K $364.3K
YoY Change 146.44% -56.4% 180.67%
Accrued Expenses $601.7K $457.3K $5.455K
YoY Change 10930.8% 458.95% -93.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $1.975M $0.00 $64.06K
YoY Change 2982.91% -100.0%
Total Short-Term Liabilities $3.912M $1.502M $787.2K
YoY Change 396.98% 24.0% -18.91%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.820M $1.434M
YoY Change -100.0% 41.61% 270.41%
Other Long-Term Liabilities $78.70K $100.6K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $78.70K $1.921M $1.434M
YoY Change -94.51% 49.44% 200.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.912M $1.502M $787.2K
Total Long-Term Liabilities $78.70K $1.921M $1.434M
Total Liabilities $3.991M $3.422M $2.221M
YoY Change 79.7% 37.1% 53.31%
SHAREHOLDERS EQUITY
Retained Earnings -$47.26M -$44.74M -$38.73M
YoY Change 22.0% 20.17% 20.39%
Common Stock $53.12M $53.01M $39.18M
YoY Change 35.56% 35.62% 19.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.864M $8.265M $450.8K
YoY Change
Total Liabilities & Shareholders Equity $9.855M $11.69M $2.672M
YoY Change 268.87% 168.69% 33.8%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.513M -$1.825M -$1.502M
YoY Change 67.29% 40.73% -130.96%
Depreciation, Depletion And Amortization $24.72K $7.460K $770.00
YoY Change 3110.39% 1916.22% 113.89%
Cash From Operating Activities -$1.969M -$1.487M -$1.786M
YoY Change 10.24% -24.7% 18.81%
INVESTING ACTIVITIES
Capital Expenditures -$54.04K -$26.66K -$7.230K
YoY Change 647.44%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$54.04K -$26.66K -$7.230K
YoY Change 647.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -83.72K 7.417M 38.00K
YoY Change -320.32% 21.66% -98.11%
NET CHANGE
Cash From Operating Activities -1.969M -1.487M -1.786M
Cash From Investing Activities -54.04K -26.66K -7.230K
Cash From Financing Activities -83.72K 7.417M 38.00K
Net Change In Cash -2.107M 5.903M -1.755M
YoY Change 20.02% 43.21% -443.72%
FREE CASH FLOW
Cash From Operating Activities -$1.969M -$1.487M -$1.786M
Capital Expenditures -$54.04K -$26.66K -$7.230K
Free Cash Flow -$1.915M -$1.460M -$1.779M
YoY Change 7.65% 18.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.05
dei Entity Central Index Key
EntityCentralIndexKey
0001516551
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55136
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
476108455 shares
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Registrant Name
EntityRegistrantName
Skye Bioscience, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0692882
dei Entity Address Address Line1
EntityAddressAddressLine1
11250 El Camino Real,
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
410-0266
dei Security12g Title
Security12gTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
SKYE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11089624 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2469410 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4570 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4566 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
321497 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
190409 USD
CY2021Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
18125 USD
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
11433816 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
2664385 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80297 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7341 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
164673 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8309 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2021Q3 us-gaap Assets
Assets
11687095 USD
CY2020Q4 us-gaap Assets
Assets
2671726 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
318982 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
364340 USD
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
20000 USD
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
17032 USD
CY2021Q3 skye Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
130824 USD
CY2020Q4 skye Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
44087 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
262881 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
61547 USD
CY2021Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
0 USD
CY2020Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
64062 USD
CY2021Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
497390 USD
CY2020Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
197564 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
207916 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
38567 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63581 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1501574 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
787199 USD
CY2021Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
0 USD
CY2020Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
52638 USD
CY2021Q3 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
450000 USD
CY2020Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
450000 USD
CY2021Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1370156 USD
CY2020Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
931103 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100583 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities
Liabilities
3422313 USD
CY2020Q4 us-gaap Liabilities
Liabilities
2220940 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
476108455 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
476108455 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
288074415 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
288074415 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
476108 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
288074 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52532017 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38896693 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44743343 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-38733981 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
8264782 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11687095 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2671726 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
327731 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
346217 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1818059 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1574357 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1491378 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1192003 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3567985 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3395729 USD
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
1819109 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
1538220 USD
us-gaap Operating Expenses
OperatingExpenses
5386044 USD
us-gaap Operating Expenses
OperatingExpenses
4970086 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1819109 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1538220 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-5386044 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-4970086 USD
CY2021Q3 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-189649 USD
CY2020Q3 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-424138 USD
skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
169349 USD
skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-433688 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
195358 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
182614 USD
us-gaap Interest Expense
InterestExpense
570322 USD
us-gaap Interest Expense
InterestExpense
520594 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
117953 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5709 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
241524 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-621718 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-86906 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1824818 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1296696 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6007762 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5056992 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1824818 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1824818 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1296696 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1296696 USD
us-gaap Net Income Loss
NetIncomeLoss
-6009362 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6009362 USD
us-gaap Net Income Loss
NetIncomeLoss
-5058592 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5058592 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-169349 USD
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
413489603 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256758472 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376547498 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
207536173 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
414461032 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257255653 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376547498 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
208434966 shares
us-gaap Net Income Loss
NetIncomeLoss
-6009362 USD
us-gaap Net Income Loss
NetIncomeLoss
-5058592 USD
us-gaap Depreciation
Depreciation
9412 USD
us-gaap Depreciation
Depreciation
1096 USD
us-gaap Share Based Compensation
ShareBasedCompensation
747252 USD
us-gaap Share Based Compensation
ShareBasedCompensation
241216 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
433688 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
439053 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
402624 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
117953 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
131088 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-40686 USD
skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
18125 USD
skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
0 USD
skye Increase Decrease In Other Assets Due From Related Parties
IncreaseDecreaseInOtherAssetsDueFromRelatedParties
8309 USD
skye Increase Decrease In Other Assets Due From Related Parties
IncreaseDecreaseInOtherAssetsDueFromRelatedParties
0 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-72719 USD
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
601823 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
2968 USD
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
11400 USD
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
86737 USD
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
81813 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
201334 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
0 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
201861 USD
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-156576 USD
skye Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
6442 USD
skye Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4506032 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4268198 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36828 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36828 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9301 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
450000 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11089624 USD
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
0 USD
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
116700 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
851538 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
854078 USD
skye Proceeds From Sale Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssuanceCosts
6146496 USD
skye Proceeds From Sale Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromSaleOfCommonStockAndWarrantsNetOfIssuanceCosts
6085589 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4783 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13163078 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6662822 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8620218 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2394624 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1834515 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11094194 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4229139 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11094194 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4229139 USD
us-gaap Interest Paid Net
InterestPaidNet
44087 USD
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4224601 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4570 USD
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4538 USD
us-gaap Interest Paid Net
InterestPaidNet
35645 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1600 USD
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1600 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
39607 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
skye Establishment Of Right Of Use Asset
EstablishmentOfRightOfUseAsset
170606 USD
skye Establishment Of Right Of Use Asset
EstablishmentOfRightOfUseAsset
0 USD
skye Accrued Financing Charges
AccruedFinancingCharges
83722 USD
skye Accrued Financing Charges
AccruedFinancingCharges
0 USD
skye Exercise Of Warrants
ExerciseOfWarrants
0 USD
skye Exercise Of Warrants
ExerciseOfWarrants
26563 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28709 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2024027 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
548058 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
64142 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-2341660 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-1702897 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1420236 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-3094424 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148365 USD
CY2020Q3 skye Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
6085589 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-1296696 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1853367 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146580 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2478649 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111699 USD
CY2021Q3 skye Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
6062774 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44743343 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2271104 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
485723 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-1824818 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
8264782 USD
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11089624 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
117953 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
7011799 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements as to the appropriate carrying values of equity instruments, derivative liabilities, debt with embedded features, and the valuation of stock based compensation awards, which are not readily apparent from other sources.</span></div>
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2020Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
1877938 USD
CY2021Q3 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
2501632 USD
CY2021Q3 skye Research And Development Licensed Technology Costs Capitalized To Date
ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate
0 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1824818 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1296696 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6009362 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5058592 USD
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
413489603 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
256758472 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
376547498 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
207536173 shares
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
414461032 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
257255653 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1704980 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1720835 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6009362 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-5401484 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
376547498 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
208434966 shares
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2020Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
41149 USD
CY2019Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
501400 USD
skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433688 USD
skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
-26563 USD
skye Class Of Warrant Or Right Warrants Vested And Outstanding
ClassOfWarrantOrRightWarrantsVestedAndOutstanding
154583892 shares
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38567 USD
skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
169349 USD
skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 USD
CY2021Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
207916 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
437834 USD
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
420 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
90797 USD
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
410603 USD
CY2020Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
41149 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
401507 USD
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
44086 USD
CY2020Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
44087 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
130824 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
117459 USD
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
294 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
445 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
511 USD
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
150852 USD
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
137849 USD
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
384 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1219 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1117 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
195358 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
182614 USD
us-gaap Interest Expense
InterestExpense
570322 USD
us-gaap Interest Expense
InterestExpense
520594 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
40000 shares
CY2021Q3 skye Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Service Contracts Day Threshold For Shares To Be Issued
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsServiceContractsDayThresholdForSharesToBeIssued
P30D
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M9D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
106250 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
22050000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.06
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M7D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2475000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.14
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
106250 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
888750 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.05
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
23490000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M17D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
8690000 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
13281 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4783 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.14
CY2021Q3 skye Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Successive Service Contracts
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfSuccessiveServiceContracts
2 contract
CY2021Q3 skye Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Service Contract Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsServiceContractPeriod
P6M
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
488973 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
148365 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
747252 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
241216 USD
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
860985 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M3D
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 skye Lessee Operating Lease Abatement Term
LesseeOperatingLeaseAbatementTerm
P2M
CY2021Q3 skye Lessee Operating Lease Initial Monthly Rent
LesseeOperatingLeaseInitialMonthlyRent
8067 USD
CY2021Q3 skye Lessee Operating Lease Annual Rent Increase Percent
LesseeOperatingLeaseAnnualRentIncreasePercent
0.03
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
7558 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
7558 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y29D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8067 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
97291 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
83093 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
188451 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24287 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
164164 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
63581 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
100583 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
164164 USD

Files In Submission

Name View Source Status
0001516551-21-000020-index-headers.html Edgar Link pending
0001516551-21-000020-index.html Edgar Link pending
0001516551-21-000020.txt Edgar Link pending
0001516551-21-000020-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skye-20210930.htm Edgar Link pending
skye-20210930.xsd Edgar Link pending
skye-20210930xex311.htm Edgar Link pending
skye-20210930xex312.htm Edgar Link pending
skye-20210930xex321.htm Edgar Link pending
skye-20210930xex322.htm Edgar Link pending
skye-20210930_cal.xml Edgar Link unprocessable
skye-20210930_def.xml Edgar Link unprocessable
skye-20210930_htm.xml Edgar Link completed
skye-20210930_lab.xml Edgar Link unprocessable
skye-20210930_pre.xml Edgar Link unprocessable